v3.23.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Mar. 31, 2022
Current assets:    
Cash and cash equivalents $ 376,532 $ 493,817
Accounts receivable 700 12,229
Prepaid expenses and other current assets 26,916 6,253
Income tax receivable 185 632
Total current assets 404,333 512,931
Operating lease right-of-use assets 1,172 2,303
Property and equipment, net 333 330
Total assets 405,838 515,564
Current liabilities:    
Accounts payable 1,353 18,629
Accrued expenses 40,421 24,575
Current portion of operating lease liabilities 1,173 1,145
Due to Roivant Sciences Ltd. 350 171
Total current liabilities 43,297 44,520
Operating lease liabilities, net of current portion 47 1,219
Total liabilities 43,344 45,739
Commitments and contingencies (Note 10)
Stockholders’ equity:    
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 130,329,863 shares issued and outstanding at March 31, 2023 and 500,000,000 shares authorized, 116,482,899 shares issued and outstanding at March 31, 2022 13 12
Additional paid-in capital 927,976 824,796
Accumulated other comprehensive income 852 404
Accumulated deficit (566,347) (355,387)
Total stockholders’ equity 362,494 469,825
Total liabilities and stockholders’ equity 405,838 515,564
Series A Preferred Stock    
Stockholders’ equity:    
Preferred stock 0 0
Preferred Stock    
Stockholders’ equity:    
Preferred stock $ 0 $ 0

Source